Novartis Secures EU Approval for Rhapsido: A New O...
Category : Approval/Launch 28 April 2026The treatment landscape for chronic spontaneous urticaria (CSU) just shifted. Novartis has secured E...
Approval Launch
Johnson & Johnson’s IMAAVY Secures FDA Priority Re...
Category : Approval/Launch 28 April 2026Johnson & Johnson has received Priority Review designation from the U.S. Food and Drug Administr...
Apotex, Orbicular & Gland Pharma Secure Dual ANDA...
Category : Approval/Launch 17 April 2026In a market where complexity often deters competition, three companies have just executed a near tex...
GSK Expands Exdensur’s Reach in China: A New Optio...
Category : Approval/Launch 10 April 2026Global biopharma leader GSK plc has secured another regulatory win in China. China’s Nation...
Cipla Expands U.S. Respiratory Portfolio with Appr...
Category : Approval/Launch 3 April 2026Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087) (NSE: CIPLA) (hereafter ref...
Latest Newsletter Post
-
Cirius Therapeutics Targets Postpar..
29 April 2026
-
Paradigm Health and FDA Pilot a Rea..
29 April 2026
-
Ascletis Advances ASC30: A New Oral..
29 April 2026
-
Johnson & Johnson’s IMAAVY Secures..
28 April 2026
-
AbbVie Files for Subcutaneous Induc..
28 April 2026
Subscribe to Our Newsletter!
C-89, Sector-65 Noida-U.P. 201301 (India)
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Customer Care: 18004190155
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com